🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

24 results for “Samsung” Clear

  1. Bevacizumab

    Samsung Bioepis NL B.V.

    Lung Cancer

    phase 3 small molecule completed

    1 trial

  2. Intermittent hepatic inflow occlusion (IHIO)

    Samsung Bioepis NL B.V.

    End Stage Liver Disease

    phase 3 other active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Samsung Bioepis NL B.V.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. SB11 (Proposed ranibizumab biosimilar)

    Samsung Bioepis NL B.V.

    Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  5. AZD2014

    Samsung Bioepis NL B.V.

    Cancer of Stomach

    phase 2 small molecule terminated

    1 trial

  6. AZD9291

    Samsung Bioepis NL B.V.

    Non-Small Cell Lung Cancer With EGFR T790M Mutation

    phase 2 small molecule active

    1 trial

  7. Byooviz 10 mg/ml solution for injection

    Samsung Bioepis NL B.V.

    Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)

    phase 2 small molecule active

    1 trial

  8. Carfilzomib 56 MG [Kyprolis]

    Samsung Bioepis NL B.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  9. Docetaxel + Sunitinib

    Samsung Bioepis NL B.V.

    Advanced Gastric Cancer

    phase 2 small molecule completed

    1 trial

  10. Evogliptin

    Samsung Bioepis NL B.V.

    Type2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  11. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  12. Pemetrexed

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  13. Zydena (Udenafil)

    Samsung Bioepis NL B.V.

    Vascular Dementia

    phase 2 small molecule active

    1 trial

  14. avelumab

    Samsung Bioepis NL B.V.

    Lymphoma, Extranodal NK-T-Cell

    phase 2 small molecule active

    1 trial

  15. vistusertib (AZD2014)

    Samsung Bioepis NL B.V.

    Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  16. A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors

    Samsung Bioepis NL B.V.

    advanced refractory solid tumors

    phase 1 other active

    1 trial

  17. PNEUMOSTEM®

    Samsung Bioepis NL B.V.

    Pulmonary Arterial Hypertension (PAH)

    phase 1 mab active

    1 trial

  18. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  19. Rebamipide 2% ophthalmic solution

    Samsung Bioepis NL B.V.

    Dry Eye Disease (DED)

    approved small molecule active

    1 trial

  20. doxazosin plus tolterodine SR

    Samsung Bioepis NL B.V.

    Overactive Bladder

    approved small molecule completed

    1 trial

  21. Lidocaine IV

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    small molecule completed

    1 trial

  22. POHIM-RT

    Samsung Bioepis NL B.V.

    Cervix Cancer

    other active

    1 trial

  23. Placebo (for Motilitone)

    Samsung Bioepis NL B.V.

    Dyspepsia

    small molecule completed

    1 trial

  24. SSRI treated group

    Samsung Bioepis NL B.V.

    Depression

    small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources